<DOC>
	<DOCNO>NCT00356369</DOCNO>
	<brief_summary>Meningococcal disease mostly cause N. meningitidis serogroups A , B , C , W-135 , Y. Meningococcal polysaccharide-conjugate vaccine advantage induce T-cell dependant immune response exist polysaccharide vaccine induce T-cell independent response , i.e . immune memory response . GSK Biologicals develop combine Men ACWY conjugate vaccine intend protect meningococcal disease due serogroups A , C , W-135 Y . In vaccination phase study , new MenACWY-TT conjugate vaccine evaluate adolescent adult use Mencevax™ ACWY control . In long-term follow-up phase ( extension phase ) study , long-term protection offer new MenACWY-TT conjugate vaccine assess five year vaccination adolescent adult use Mencevax™ ACWY control . This protocol post deal objective &amp; outcome measure primary &amp; extension phase .</brief_summary>
	<brief_title>Study Adolescents/Adults Evaluate Non-inferiority &amp; Persistence 5 Years GSK Bio MenACWY Conjugate Vaccine</brief_title>
	<detailed_description>All subject 7 blood sample take : prior one month vaccination one , two , three , four five year vaccination . No new subject enrol extension phase Phase IIb study . The Protocol Posting update order comply FDA Amendment Act , September 2007 .</detailed_description>
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe and/or parents/ legally acceptable representative comply requirement protocol . A male female , include , 11 55 year age time vaccination . Written inform consent obtain subject/ parent legally acceptable representative subject . Free obvious health problem establish medical history clinical examination enter study . Previously complete routine childhood vaccination best his/her knowledge and/or his/her parents/legally acceptable representative 's knowledge . If subject female , must nonchildbearing potential ; , childbearing potential , must abstinent use adequate contraceptive precaution 30 day prior vaccination , must agree continue precaution two month completion vaccination series . Female subject childbearing potential abstinent must negative pregnancy test . Use investigational nonregistered product ( drug vaccine ) study vaccine ( ) within 30 day precede dose study vaccine , plan use study period . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug within six month prior vaccine dose . Planned administration/ administration vaccine foreseen study protocol within one month dose vaccine ( ) . Previous vaccination meningococcal polysaccharide vaccine serogroup A , C W and/or Y within last five previous year . Previous vaccination meningococcal polysaccharide conjugate vaccine serogroup A , C W and/or Y . History meningococcal disease due serogroup A , C , W Y . Any confirm suspected immunosuppressive immunodeficient condition , include human immunodeficiency virus ( HIV ) infection . A family history congenital hereditary immunodeficiency . History allergic disease reaction likely exacerbate component vaccine . Major congenital defect serious chronic illness . History neurologic disorder seizure . History GuillainBarré syndrome . Acute disease time enrolment . Administration immunoglobulins and/or blood product within three month precede first dose study vaccine plan administration study period . Pregnant lactate female . History chronic alcohol consumption and/or drug abuse . Female plan become pregnant planning discontinue contraceptive precaution . Specific criterion check study visit long term followup : History meningococcal serogroup A , C , W Y disease . Administration meningococcal polysaccharide meningococcal polysaccharide conjugate vaccine plan protocol .</criteria>
	<gender>All</gender>
	<minimum_age>11 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Immunogenicity</keyword>
	<keyword>Healthy</keyword>
	<keyword>Persistence</keyword>
	<keyword>Meningococcal vaccine</keyword>
	<keyword>Non-inferiority</keyword>
	<keyword>Meningococcal A C W Y Diseases</keyword>
	<keyword>meningococcal serogroups A , C , W &amp; Y disease</keyword>
</DOC>